DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Provided By PR Newswire
Last update: Mar 26, 2025
Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025
Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH)
Read more at prnewswire.com
